Você procurou por: scn (Inglês - Maltês)

scn
scn

scn patients
f’pazjenti b’scn

in scn patients
f’ pazjenti b’scn

in patients with scn
f’pazjenti b’scn

special precautions in scn patients
prekawzjonijiet speċjali f’pazjenti b’scn

severe chronic neutropenia (scn)
newtropenja kronika severa (scn)

scn/ hiv infection subcutaneous injection.
infezzjoni b’ scn/ hiv injezzjoni taħt il- ġilda.

email: scot50@scn-net.org
posta elettronika: scot50@scn-net.org

paediatric use in the scn and cancer settings
użu fil-pedjatrija f’każ ta’ scn u kanċer

paediatric patients in the scn and cancer settings
pazjenti pedjatriċi li għandhom scn u kanċer

in patients with severe chronic neutropenia (scn)
f’pazjenti b’newtropenja kronika u qawwija (scn)

in patients with severe chronic neutropenia (scn) congenital neutropenia
f’pazjenti b’newtropenija kronika severa (scn) newtropenija konġenitali

there were no differences in the safety profiles for paediatric patients treated for scn.
ma kien hemm ebda differenza fil-profili ta’ sigurtà għal pazjenti pedjatriċi kkurati għal scn.

during long term use cutaneous vasculitis has been reported in 2% of scn patients.
meta ntuża fit-tul, infjammazzjoni vaskulari fil-ġilda giet irraportata fit-2 % tal-pazjenti b’scn.

during long term use, cutaneous vasculitis has been reported in 2 % of scn patients.
meta ntuża fit-tul, infjammazzjoni vaskulari fil-ġilda giet irraportata fit-2% tal-pazjenti b’newtropenja qawwija u kronika.

undesirable effects related to filgrastim therapy in scn patients have been reported and for some their frequencies tend to decrease with time.
kien hemm rapporti ta’ effetti mhux mixtieqa relatati ma’ kura ta’ filgrastim f’pazjenti b’scnu,għal xi whud, il-frekwenza tagħhom kellha tendenza li tonqos maż-żmien.

in scn patients, the most frequent undesirable effects attributable to filgrastim were bone pain, general musculoskeletal pain and splenomegaly.
f’pazjenti b’scn l-aktar effetti mhux mixtieqa frekwenti attribwibbli għal filgrastim kienu wġigħ fl- għadam, uġigħ muskolskeletriku ġenerali u splenomegalija.

20 paediatric patients in the scn and cancer settings in clinical studies 65% of patients treated for scn were younger than 18 years.
pazjenti pedjatriċi li għandhom scn u kanċer fi studji kliniċi 65% ta ’ pazjenti kkurati għal scn kellhom inqas minn 18- il sena.

it is currently unclear whether long-term treatment of patients with scn will predispose patients to cytogenetic abnormalities, mds or leukaemic transformation.
bħalissa mhuwiex ċert jekk il-kura fit-tul b’filgrastim f’pazjenti b’scnjippredisponi dan il-grupp ta’ pazjenti għal parametri ċitoġenetiċi abnormali, mds jew lewkimja.

there was a low frequency (approximately 3 %) of myelodysplastic syndromes (mds) or leukaemia in clinical trial patients with scn treated with filgrastim.
fi studji kliniċi, kien hemm frewkwenza baxxa (madwar 3%) ta’ sindromi majelodisplastiċi (mds) jew lewkimja f’pazjenti b’scn ikkurati b’filgrastim.